Compositions and methods for promoting skin regeneration and hair growth

• US 10,105,305 B2
• Filed: 02/19/2015
• Issued: 10/23/2018
• Est. Priority Date: 02/19/2014
• Status: Active Grant

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Garza, Luis Andres, Nelson, Amanda Marie
• Primary Examiner(s): Steele, Amber D
• Application Number:
  US15/120,189
• Publication Number:
  US 20170056310A1
• Time in Patent Office: 1,342 Days
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 8/606 Nucleosides; Nucleotides; Nucleic acids
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61Q 7/00 Preparations for affecting hair growth
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 15/117 Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• CPC Class Codes: C12N 2310/17 Immunomodulatory nucleic acids
• CPC Class Codes: C12N 2320/31 Combination therapy

Abstract

The present invention relates to the field of wound healing. Specifically, the present invention provides compositions and methods for promoting skin regeneration, more specifically, the generation of de novo hair follicles. In one embodiment, a method for stimulating hair follicle neogenesis in a subject comprises the step of administering to the subject an effective amount of a TLR3 agonist. In certain embodiments, the TLR3 agonist is a double stranded RNA (dsRNA). The present invention is also directed to treating common male pattern hair loss.

Claims

1. A method for stimulating hair follicle neogenesis in a subject comprising the step of administering to the subject an effective amount of a TLR3 agonist.

2. The method of claim 1, wherein the TLR3 agonist is a double stranded RNA (dsRNA).

3. The method of claim 1, wherein the subject has alopecia.

4. The method of claim 1, wherein the subject is bald.

5. The method of claim 1, wherein the subject has a wound.

6. The method of claim 1, wherein the TLR3agonist is administered directly to a site on the subject that requires hair follicle neogenesis.

7. The method of claim 6, wherein the TLR3 agonist is administered topically.

8. The method of claim 7, wherein the TLR3 agonist is administered by injection.

9. The method of claim 1, wherein the TLR 3 agonist is Polyinosinic:

polycytidylic acid (Poly I;

C).

16. The method of claim 1, further comprising administering an effective amount of LL-37.

10. A method for treating common male pattern hair loss in a subject comprising the step of administering to the subject an effective amount of a TLR3 agonist.

11. The method of claim 10, wherein the TLR3 agonist is a double stranded RNA (dsRNA).

12. The method of claim 10, wherein the TLR3 agonist is administered directly to the site of hair loss on the subject.

13. The method of claim 12, wherein the TLR3 agonist is administered topically.

14. The method of claim 12, wherein the TLR3 agonist is administered by injection.

15. The method of claim 10, wherein the TLR3 agonist is Polyinosinic:

polycytidylic acid (Poly I;

C).